• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

ZIPRASIDONE Drug Record

  • Summary
  • Interactions
  • Claims
  • ZIPRASIDONE chembl:CHEMBL708 Approved

    Alternate Names:

    GEODON
    CP-88059
    ZIPRASIDONE
    CP-88059-27
    CP-880591
    ZIPRASIDONE HYDROCHLORIDE
    ZIPRASIDONUM
    ZIPRASIDONA
    CP-8805927
    GEODON®
    rxcui:115698
    pubchem.compound:60854
    chembl:CHEMBL708
    drugbank:00246
    chemidplus:146939-27-7

    Drug Info:

    FDA Approval approved
    Drug Class small molecule
    Drug Indications antipsychotic agent
    Drug Class antipsychotic agents
    Year of Approval 2001
    Drug Categories adrenergic alpha-1 receptor antagonists
    Drug Categories adrenergic alpha-antagonists
    Drug Categories adrenergic antagonists
    Drug Categories agents that produce hypertension
    Drug Categories anticholinergic agents
    Drug Categories antidepressive agents
    Drug Categories cytochrome p-450 cyp2d6 inhibitors (weak)
    Drug Categories cytochrome p-450 cyp3a substrates
    Drug Categories cytochrome p-450 cyp3a4 inhibitors
    Drug Categories cytochrome p-450 cyp3a4 substrates (strength unknown)
    Drug Categories cytochrome p-450 cyp3a5 substrates
    Drug Categories cytochrome p-450 enzyme inhibitors
    Drug Categories cytochrome p-450 substrates
    Drug Categories dopamine d2 receptor antagonists
    Drug Categories histamine antagonists
    Drug Categories histamine h1 antagonists
    Drug Categories muscarinic antagonists
    Drug Categories neurotoxic agents
    Drug Categories qtc prolonging agents
    Drug Categories serotonergic drugs shown to increase risk of serotonin syndrome
    Drug Categories serotonin 5-ht1 receptor agonists
    Drug Categories serotonin 5-ht1 receptor antagonists
    Drug Categories serotonin 5-ht2 receptor antagonists
    Drug Categories serotonin receptor agonists
    Drug Categories serotonin receptor antagonists
    (4 More Sources)

    Publications:

    Nasrallah, 2008, Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles., Mol. Psychiatry
    Imming et al., 2006, Drugs, their targets and the nature and number of drug targets., Nat Rev Drug Discov
    Overington et al., 2006, How many drug targets are there?, Nat Rev Drug Discov
    Andersohn et al., 2010, Priapism associated with antipsychotics: role of alpha1 adrenoceptor affinity., J Clin Psychopharmacol
    Stahl et al., 2003, The psychopharmacology of ziprasidone: receptor-binding properties and real-world psychiatric practice., J Clin Psychiatry
    Seeman, 2002, Atypical antipsychotics: mechanism of action., Can J Psychiatry
    Seeger et al., 1995, Ziprasidone (CP-88,059): a new antipsychotic with combined dopamine and serotonin receptor antagonist activity., J. Pharmacol. Exp. Ther.
    Chen et al., 2002, TTD: Therapeutic Target Database., Nucleic Acids Res.
    Kopecek et al., 2005, Ziprasidone-induced galactorrhea: a case report., Neuro Endocrinol. Lett.
    Richelson et al., 2000, Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds., Life Sci.
    Sprouse et al., 1999, Comparison of the novel antipsychotic ziprasidone with clozapine and olanzapine: inhibition of dorsal raphe cell firing and the role of 5-HT1A receptor activation., Neuropsychopharmacology
    Wilner et al., 2002, The anxiolytic effect of the novel antipsychotic ziprasidone compared with diazepam in subjects anxious before dental surgery., J Clin Psychopharmacol
    Cates ME, 2003, Ziprasidone--not an option for serotonin syndrome., CMAJ
    Zanger UM et al., 2008, Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformation., Anal Bioanal Chem
    Wood et al., 2006, Pharmacological profile of antipsychotics at monoamine receptors: atypicality beyond 5-HT2A receptor blockade., CNS Neurol Disord Drug Targets
    Sánchez et al., 2000, In-vivo assessment of 5-HT2A and 5-HT2C antagonistic properties of newer antipsychotics., Behav Pharmacol
    Arnt, 1995, Differential effects of classical and newer antipsychotics on the hypermotility induced by two dose levels of D-amphetamine., Eur. J. Pharmacol.
    Schmidt et al., 2001, Ziprasidone: a novel antipsychotic agent with a unique human receptor binding profile., Eur. J. Pharmacol.
    Newman-Tancredi et al., 2003, Comparison of hippocampal G protein activation by 5-HT(1A) receptor agonists and the atypical antipsychotics clozapine and S16924., Naunyn Schmiedebergs Arch. Pharmacol.
    Rollema et al., 2000, 5-HT(1A) receptor activation contributes to ziprasidone-induced dopamine release in the rat prefrontal cortex., Biol. Psychiatry
    Mansbach et al., Blockade of drug-induced deficits in prepulse inhibition of acoustic startle by ziprasidone., Pharmacol. Biochem. Behav.
    Kast et al., 2007, Treatment schedules for 5-HT2A blocking in progressive multifocal leukoencephalopathy using risperidone or ziprasidone., Bone Marrow Transplant.
    Ichikawa et al., 2002, Atypical antipsychotic drugs, quetiapine, iloperidone, and melperone, preferentially increase dopamine and acetylcholine release in rat medial prefrontal cortex: role of 5-HT1A receptor agonism., Brain Res.
    Lu et al., 2002, A case of ziprasidone-induced mania and the role of 5-HT2A in mood changes induced by atypical antipsychotics., J Clin Psychiatry
    Mamo et al., 2004, A PET study of dopamine D2 and serotonin 5-HT2 receptor occupancy in patients with schizophrenia treated with therapeutic doses of ziprasidone., Am J Psychiatry
    Stark et al., 2007, Interaction of the novel antipsychotic aripiprazole with 5-HT1A and 5-HT 2A receptors: functional receptor-binding and in vivo electrophysiological studies., Psychopharmacology (Berl.)
    Meltzer, 1995, Role of serotonin in the action of atypical antipsychotic drugs., Clin. Neurosci.
    Meltzer, 1999, The role of serotonin in antipsychotic drug action., Neuropsychopharmacology
    Zhang JP et al., 2016, Pharmacogenetic Associations of Antipsychotic Drug-Related Weight Gain: A Systematic Review and Meta-analysis., Schizophr Bull
    Czerwensky F et al., 2013, MC4R rs489693: a clinical risk factor for second generation antipsychotic-related weight gain?, Int J Neuropsychopharmacol
    Nurmi EL et al., 2013, Moderation of antipsychotic-induced weight gain by energy balance gene variants in the RUPP autism network risperidone studies., Transl Psychiatry
    Malhotra AK et al., 2012, Association between common variants near the melanocortin 4 receptor gene and severe antipsychotic drug-induced weight gain., Arch Gen Psychiatry
    Thompson AJ et al., 2006, 5-HT3 receptors., Curr Pharm Des
    Drago A et al., 2014, Genome-wide association study supports the role of the immunological system and of the neurodevelopmental processes in response to haloperidol treatment., Pharmacogenet Genomics
    Nelson DL, 2004, 5-HT5 receptors., Curr Drug Targets CNS Neurol Disord
  • ZIPRASIDONE   EIF2AK4

    Interaction Score: 0.46

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    24751813


    Sources:
    PharmGKB

  • ZIPRASIDONE   MC4R

    Interaction Score: 0.45

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    27217270 23920449 23799528 22566560


    Sources:
    PharmGKB

  • ZIPRASIDONE   HTR5A

    Interaction Score: 0.29

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:

    PMIDs:
    14965244 17848919


    Sources:
    DrugBank

  • ZIPRASIDONE   HTR1D

    Interaction Score: 0.22

    Interaction Types & Directionality:
    antagonist (inhibitory)
    agonist (activating)

    Interaction Info:
    Specific Action of the Ligand Full agonist
    Endogenous Drug? False

    PMIDs:
    11132243 7562537 10516958 11910268 14728084 14638642


    Sources:
    DrugBank TEND GuideToPharmacology

  • ZIPRASIDONE   HTR7

    Interaction Score: 0.17

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:
    Endogenous Drug? False
    Specific Action of the Ligand Inverse agonist

    PMIDs:
    17242925 7583621 10432496 17848919


    Sources:
    DrugBank TEND GuideToPharmacology

  • ZIPRASIDONE   HTR1E

    Interaction Score: 0.14

    Interaction Types & Directionality:
    agonist (activating)
    antagonist (inhibitory)

    Interaction Info:
    Endogenous Drug? False
    Specific Action of the Ligand Full agonist

    PMIDs:
    17848919


    Sources:
    DrugBank GuideToPharmacology

  • ZIPRASIDONE   HTR1A

    Interaction Score: 0.12

    Interaction Types & Directionality:
    agonist (activating)

    Interaction Info:
    Specific Action of the Ligand Partial agonist
    Endogenous Drug? False

    PMIDs:
    11513838 11910268 14728084 12923612 10924666 11132243 10516958 14638642


    Sources:
    DrugBank TEND GuideToPharmacology

  • ZIPRASIDONE   HTR2C

    Interaction Score: 0.11

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:
    Specific Action of the Ligand Inverse agonist
    Endogenous Drug? False
    Direct Interaction? True

    PMIDs:
    11132243 16918396 11103883 7562537 14728084 14638642


    Sources:
    DrugBank TEND GuideToPharmacology

  • ZIPRASIDONE   DRD4

    Interaction Score: 0.11

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:

    PMIDs:
    17016423 17139284 17848919


    Sources:
    DrugBank TEND

  • ZIPRASIDONE   HTR2A

    Interaction Score: 0.09

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:
    Direct Interaction? True
    Endogenous Drug? False
    Specific Action of the Ligand Antagonist

    PMIDs:
    11509214 14728084 17450180 12445705 17848919 12530423 15121646


    Sources:
    DrugBank TdgClinicalTrial TEND GuideToPharmacology

  • ZIPRASIDONE   DRD5

    Interaction Score: 0.09

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:

    PMIDs:
    17848919


    Sources:
    DrugBank

  • ZIPRASIDONE   DRD2

    Interaction Score: 0.09

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:
    Direct Interaction? True
    Endogenous Drug? False
    Specific Action of the Ligand Antagonist

    PMIDs:
    14728084 11873706 7562537 11752352 17848919 15726024


    Sources:
    DrugBank TdgClinicalTrial TEND GuideToPharmacology TTD

  • ZIPRASIDONE   HTR1B

    Interaction Score: 0.08

    Interaction Types & Directionality:
    agonist (activating)
    antagonist (inhibitory)

    Interaction Info:
    Specific Action of the Ligand Full agonist
    Endogenous Drug? False

    PMIDs:
    17848919 11513838


    Sources:
    DrugBank GuideToPharmacology

  • ZIPRASIDONE   DRD3

    Interaction Score: 0.08

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:

    PMIDs:
    17016423 17139284 17848919


    Sources:
    DrugBank TEND

  • ZIPRASIDONE   HTR3A

    Interaction Score: 0.08

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:

    PMIDs:
    17848919 17073663


    Sources:
    DrugBank

  • ZIPRASIDONE   HTR6

    Interaction Score: 0.06

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:

    PMIDs:
    17848919


    Sources:
    DrugBank

  • ZIPRASIDONE   HRH1

    Interaction Score: 0.05

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:
    Specific Action of the Ligand Antagonist
    Endogenous Drug? False

    PMIDs:
    11132243 7498321 17848919


    Sources:
    DrugBank TEND GuideToPharmacology

  • ZIPRASIDONE   CHRM4

    Interaction Score: 0.04

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:

    PMIDs:
    17848919


    Sources:
    DrugBank

  • ZIPRASIDONE   CHRM5

    Interaction Score: 0.04

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:

    PMIDs:
    17848919


    Sources:
    DrugBank

  • ZIPRASIDONE   ADRA1A

    Interaction Score: 0.04

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:

    PMIDs:
    20075651 17848919


    Sources:
    DrugBank TEND

  • ZIPRASIDONE   ADRA2B

    Interaction Score: 0.04

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:

    PMIDs:
    17848919


    Sources:
    DrugBank

  • ZIPRASIDONE   CYP3A5

    Interaction Score: 0.03

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    18695978


    Sources:
    PharmGKB

  • ZIPRASIDONE   ADRA2C

    Interaction Score: 0.03

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:

    PMIDs:
    17848919


    Sources:
    DrugBank

  • ZIPRASIDONE   ADRA1B

    Interaction Score: 0.03

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:

    PMIDs:
    17848919


    Sources:
    DrugBank

  • ZIPRASIDONE   CHRM2

    Interaction Score: 0.03

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:

    PMIDs:
    17848919


    Sources:
    DrugBank

  • ZIPRASIDONE   CHRNA7

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    TTD

  • ZIPRASIDONE   ADRA2A

    Interaction Score: 0.02

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:

    PMIDs:
    17848919


    Sources:
    DrugBank

  • ZIPRASIDONE   CHRM3

    Interaction Score: 0.02

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:

    PMIDs:
    17848919


    Sources:
    DrugBank

  • ZIPRASIDONE   CHRM1

    Interaction Score: 0.02

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:

    PMIDs:
    17848919


    Sources:
    DrugBank

  • ZIPRASIDONE   SLC6A4

    Interaction Score: 0.02

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Specific Action of the Ligand Inhibition
    Endogenous Drug? False
    Direct Interaction? False

    PMIDs:
    None found


    Sources:
    GuideToPharmacology

  • ZIPRASIDONE   DRD1

    Interaction Score: 0.02

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:

    PMIDs:
    17848919


    Sources:
    DrugBank

  • ZIPRASIDONE   RGS4

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • ZIPRASIDONE   ADRB1

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    TEND

  • ZIPRASIDONE   EHMT2

    Interaction Score: 0.0

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • ZIPRASIDONE   AR

    Interaction Score: 0.0

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • DrugBank: DB00246

    • Version: 5.1.7

    Alternate Names:
    ZIPRASIDONE DrugBank Drug Name
    146939-27-7 CAS Number
    Auro-ziprasidone Drug Brand

    Drug Info:
    Drug Type small molecule
    Drug Groups approved
    Drug Categories adrenergic alpha-1 receptor antagonists

    Publications:
    Nasrallah, 2008, Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles., Mol. Psychiatry
    Imming et al., 2006, Drugs, their targets and the nature and number of drug targets., Nat Rev Drug Discov
    Overington et al., 2006, How many drug targets are there?, Nat Rev Drug Discov

  • TEND: ZIPRASIDONE

    • Version: 01-August-2011

    Alternate Names:
    ZIPRASIDONE Primary Drug Name

    Drug Info:
    Year of Approval 2001
    Drug Class antipsychotic agents

    Publications:

  • TdgClinicalTrial: ZIPRASIDONE

    • Version: January-2014

    Alternate Names:

    Drug Info:
    Drug Indications antipsychotic agent
    Drug Class small molecule
    FDA Approval approved

    Publications:

  • PharmGKB: ziprasidone

    • Version: 18-August-2020

    Alternate Names:

    Drug Info:

    Publications:
    Zanger UM et al., 2008, Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformation., Anal Bioanal Chem
    Malhotra AK et al., 2012, Association between common variants near the melanocortin 4 receptor gene and severe antipsychotic drug-induced weight gain., Arch Gen Psychiatry
    Nurmi EL et al., 2013, Moderation of antipsychotic-induced weight gain by energy balance gene variants in the RUPP autism network risperidone studies., Transl Psychiatry

  • GuideToPharmacology: 135651359

    • Version: 29-September-2020

    Alternate Names:
    ZIPRASIDONE GuideToPharmacology Ligand Name

    Drug Info:

    Publications:

  • DTC: ZIPRASIDONE

    • Version: 02-September-2020

    Alternate Names:
    CHEMBL708 ChEMBL Drug ID

    Drug Info:

    Publications:

  • TTD: Ziprasidone

    • Version: 2020.06.01

    Alternate Names:
    D0R1JV TTD Drug ID

    Drug Info:

    Publications:

  • ChemblDrugs: chembl:CHEMBL708

    • Version: ChEMBL_27

    Alternate Names:

    Drug Info:

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21